TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,792,893 | -54.6% | 983,545 | -22.0% | 0.01% | -55.0% |
| Q2 2023 | $19,369,022 | -13.8% | 1,261,004 | +26.2% | 0.02% | -16.7% |
| Q1 2023 | $22,478,553 | +129.0% | 999,491 | +114.1% | 0.02% | +118.2% |
| Q4 2022 | $9,817,646 | +6.0% | 466,840 | +24.2% | 0.01% | 0.0% |
| Q3 2022 | $9,261,000 | -10.9% | 375,843 | -12.4% | 0.01% | -8.3% |
| Q2 2022 | $10,390,000 | -15.2% | 428,827 | -9.8% | 0.01% | +9.1% |
| Q1 2022 | $12,251,000 | +13.6% | 475,401 | +36.9% | 0.01% | +22.2% |
| Q4 2021 | $10,781,000 | +9.6% | 347,341 | -14.4% | 0.01% | 0.0% |
| Q3 2021 | $9,841,000 | -43.7% | 405,837 | -66.1% | 0.01% | -40.0% |
| Q2 2021 | $17,476,000 | -52.6% | 1,197,798 | -18.9% | 0.02% | -58.3% |
| Q1 2021 | $36,868,000 | -12.4% | 1,476,479 | -4.4% | 0.04% | -5.3% |
| Q4 2020 | $42,077,000 | – | 1,543,842 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |